Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 12:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 453 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Progesterone Clear all
Completed Phase 2 Interventional Results available

Treatment of Fragile-X Associated Tremor/Ataxia Syndrome (FXTAS) With Allopregnanolone

NCT02603926
View directory record Official record
Conditions
Fragile X-associated Tremor/Ataxia Syndrome
Interventions
Allopregnanolone
Drug
Lead sponsor
Randi J. Hagerman, MD
Other
Eligibility
50 Years to 85 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Dec 6, 2018 · Synced Oct 19, 2026, 12:38 AM EDT
Terminated Not applicable Interventional

SMART-ER: Symptom Monitoring With Patient-reported Outcomes

NCT05560685
View directory record Official record
Conditions
Breast Cancer
Interventions
Outcomes4Me, Semi-structured interview
Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Oct 19, 2026, 12:38 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Midlife Cholesterol Study

NCT00361075
View directory record Official record
Conditions
Menopause, Postmenopause, Premenopause, Cardiovascular Disease
Interventions
transdermal estradiol patch (Vivelle), oral estrogen (Estrace), progesterone (Prometrium)
Drug
Lead sponsor
Northwestern University
Other
Eligibility
47 Years to 55 Years · Female only
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 2005
U.S. locations
2
States / cities
Chicago, Illinois • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 5, 2014 · Synced Oct 19, 2026, 12:38 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Bioidentical 'Natural' Hormone Evaluation in Early Menopause

NCT00302731
View directory record Official record
Conditions
Menopause
Interventions
Estradiol , estriol , progesterone, estradiol, progesterone, estriol, progesterone, equine estrogens m-progesteroneacetate
Drug
Lead sponsor
Jeanne Drisko, MD, CNS, FACN
Other
Eligibility
40 Years to 65 Years · Female only
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2014
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 6, 2018 · Synced Oct 19, 2026, 12:38 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

LATe Cerclage in High-risk Pregnancies (LATCH)

NCT06036446
View directory record Official record
Conditions
Premature Birth
Interventions
Cervical cerclage, Vaginal Suppository Progesterone
Procedure · Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
329 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2029
U.S. locations
2
States / cities
Charlotte, North Carolina • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 19, 2026, 12:38 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Progesterone & Postpartum Relapse to Smoking

NCT01798394
View directory record Official record
Conditions
Tobacco Use Cessation, Tobacco Use Disorder
Interventions
Progesterone, Placebo
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Oct 19, 2026, 12:38 AM EDT
Terminated Phase 2 Interventional Results available

Study Of Abraxane® And Carboplatin As First-Line Treatment For Triple Negative Metastatic Breast Cancer

NCT01207102
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Abraxane, Carboplatin
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 15, 2014 · Synced Oct 19, 2026, 12:38 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Impact of Vaginal and IM Progestins on the Cervix

NCT01954095
View directory record Official record
Conditions
Preterm Birth, Short Cervical Length
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
4
States / cities
Indianapolis, Indiana • Pittsburgh, Pennsylvania • Galveston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2015 · Synced Oct 19, 2026, 12:38 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer

NCT02007512
View directory record Official record
Conditions
Breast Cancer
Interventions
Enzalutamide, exemestane, Placebo (for enzalutamide)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2024
U.S. locations
89
States / cities
Aurora, Colorado • Colorado Springs, Colorado • Lakewood, Colorado + 54 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Oct 19, 2026, 12:38 AM EDT
Terminated Phase 2 Interventional Results available

Estradiol and Progesterone in Hospitalized COVID-19 Patients

NCT04865029
View directory record Official record
Conditions
Covid19
Interventions
Placebo injection and placebo pill, Estradiol Cypionate 5 mg/ml, Progesterone 200 mg Oral Capsule
Other · Drug
Lead sponsor
Tulane University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Oct 19, 2026, 12:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic Evaluation of Bioidentical Compounded Estrogen Cream and Natural Progesterone

NCT00864214
View directory record Official record
Conditions
Menopause
Interventions
bioidentical hormone (Biest), bioidentical hormone (Vivelle-Dot)
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years to 60 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 16, 2012 · Synced Oct 19, 2026, 12:38 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Hormones and Reduction in Co-users of Marijuana and Nicotine

NCT02579421
View directory record Official record
Conditions
Marijuana Dependence
Interventions
Progesterone, placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 60 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 26, 2020 · Synced Oct 19, 2026, 12:38 AM EDT
Completed Phase 3 Interventional Results available

S1202: Duloxetine Hydrochloride for Muscle/Joint Pain in Early-Stage Breast Cancer Receiving Hormone Therapy

NCT01598298
View directory record Official record
Conditions
Breast Cancer, Musculoskeletal Complications, Pain
Interventions
duloxetine hydrochloride, placebo
Drug · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Up to 120 Years · Female only
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
714
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Jonesboro, Arkansas + 475 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2022 · Synced Oct 19, 2026, 12:38 AM EDT
Completed Phase 2 Interventional Results available

Research Investigation of Soy and Estrogen

NCT00997893
View directory record Official record
Conditions
Menopause, Hot Flashes
Interventions
Soy Phytoestrogen, Estradiol, Medroxyprogesterone Acetate (MPA), Soy Placebo, MPA Placebo
Dietary Supplement · Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
40 Years to 65 Years · Female only
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 7, 2020 · Synced Oct 19, 2026, 12:38 AM EDT
Completed Not applicable Interventional Results available

Sex Differences, Hormones & Smoking Cessation

NCT01744574
View directory record Official record
Conditions
Tobacco Cessation
Interventions
Placebo, Progesterone, Smoking Cessation Behavioral Counseling
Other · Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 60 Years
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 12, 2019 · Synced Oct 19, 2026, 12:38 AM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Study of the Combination Estradiol and Progesterone to Treat Vasomotor Symptoms

NCT01942668
View directory record Official record
Conditions
Menopause
Interventions
Estradiol, Progesterone, Placebo
Drug
Lead sponsor
TherapeuticsMD
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
1,845 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
119
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 99 more
Source: ClinicalTrials.gov public record
Updated May 6, 2019 · Synced Oct 19, 2026, 12:38 AM EDT
Completed No phase listed Observational

Assessment of Candidate Protein Expression in Breast Cancer Specimens

NCT00918892
View directory record Official record
Conditions
Breast Cancer
Interventions
gene expression analysis, immunohistochemistry staining method, laboratory biomarker analysis
Genetic · Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
Not listed
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 1, 2022 · Synced Oct 19, 2026, 12:38 AM EDT
Completed Phase 3 Interventional Results available

Study in Women With Idiopathic Menorrhagia to Determine the Reduction in Menstrual Blood Loss (MBL) After Treatment With the Levonorgestrel-releasing Intrauterine System (IUS)

NCT00360490
View directory record Official record
Conditions
Menorrhagia
Interventions
Levonorgestrel IUS (Mirena, BAY86-5028), Medroxyprogesterone acetate
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Female only
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
37
States / cities
Tucson, Arizona • Beverly Hills, California • Carmichael, California + 32 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2013 · Synced Oct 19, 2026, 12:38 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Estrogen Variability and Irritability During the Menopause Transition

NCT05388656
View directory record Official record
Conditions
Menopause, Irritable Mood
Interventions
Estradiol Patch, 0.1 mg/24 Hours Weekly Transdermal Film, Extended Release, Placebo, Progesterone 200 mg
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
45 Years to 59 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Oct 19, 2026, 12:38 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Disentangling the Effects of Daily Stress, Sleep, and Sex Hormones on Accelerated Vascular Aging in Midlife Women

NCT06745466
View directory record Official record
Conditions
Estrogen, Premenopause
Interventions
ganirelix acetate
Drug
Lead sponsor
University of Delaware
Other
Eligibility
40 Years to 55 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 19, 2026, 12:38 AM EDT
Completed Not applicable Interventional

Depo-Medroxyprogesterone Acetate (DMPA, Depo-Provera) Use With Certain Anti-HIV Drugs in HIV-Infected Women

NCT00016601
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Ritonavir, Nelfinavir mesylate, Efavirenz, Nevirapine, Medroxyprogesterone acetate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older · Female only
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
31
States / cities
Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2012 · Synced Oct 19, 2026, 12:38 AM EDT
Completed Phase 2 Interventional Results available

Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer

NCT01124695
View directory record Official record
Conditions
Breast Cancer, Stage IV Breast Cancer
Interventions
tamoxifen
Drug
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
292
States / cities
Birmingham, Alabama • Mobile, Alabama • Fort Smith, Arkansas + 203 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2023 · Synced Oct 19, 2026, 12:38 AM EDT
Terminated Phase 3 Interventional

Safety of Estrogens in Lupus: Hormone Replacement Therapy

NCT00000419
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Premarin and Provera
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 85 Years · Female only
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2002
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated May 3, 2013 · Synced Oct 19, 2026, 12:38 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Effects of Estrogen on Heart Health in Women With Primary Ovarian Insufficiency

NCT06866119
View directory record Official record
Conditions
Primary Ovarian Insufficiency, Premature Menopause, Metabolic Complications, Endothelial Function (FMD), Estrogen Replacement Therapy
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
30 Years to 40 Years · Female only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 19, 2026, 12:38 AM EDT